[Therapeutic indications in herpes zoster]

Area of Science:

• Virology
• Immunology
• Dermatology

Background:

• Herpes Zoster (shingles) causes painful lesions and can lead to complications.
• Acyclovir is a standard antiviral treatment.
• Thymopentin is an immunomodulating drug with potential therapeutic benefits.

Purpose of the Study:

• To compare the efficacy of intravenous acyclovir and subcutaneous thymopentin in treating acute Herpes Zoster.
• To evaluate the drugs' effects on lesion recovery and pain relief.
• To explore thymopentin's potential anti-inflammatory and post-herpetic neuropathy prevention properties.

Main Methods:

• Fifty-two patients with acute Herpes Zoster were enrolled.
• Patients were randomized into two groups: 25 received i.v. acyclovir, and 27 received s.c. thymopentin.
• Treatment outcomes included lesion healing and pain symptomatology.

Main Results:

• Both acyclovir and thymopentin demonstrated effectiveness in promoting recovery from herpetic lesions.
• Painful symptomatology was relieved by both treatments within a similar timeframe.
• Thymopentin exhibited an apparent antiphlogistic effect.

Conclusions:

• Intravenous acyclovir and subcutaneous thymopentin are comparably effective for acute Herpes Zoster.
• Thymopentin's immunomodulating activity may help prevent post-herpetic neuropathy.
• Further large-scale studies are needed for statistical validation.